The European Medicines Agency's Committee for Orphan Medicinal Products (COMP) has published the agenda for its meeting scheduled for 11-12 May 2026. The committee will review applications for orphan designation of medicinal products intended for the treatment of rare diseases, which affect fewer than five in 10,000 people in the EU. The meeting is part of the ongoing process to incentivise research and development of therapies for conditions with limited market potential.
The COMP meeting agenda includes discussions on new applications for orphan designation, as well as follow-up on previously submitted applications. The committee may also address requests for protocol assistance, which provides scientific advice on the development of orphan medicines. Decisions taken during the meeting will be published in the EMA's monthly summary of opinions.
Stakeholder impact Pharmaceutical companies developing treatments for rare diseases are directly affected, as orphan designation offers benefits such as reduced fees, protocol assistance, and ten years of market exclusivity upon approval. Patient organisations representing rare disease communities may see new therapies progress through the pipeline. National health authorities could face future reimbursement decisions if designated products reach the market. The COMP's decisions also influence investment decisions in the rare disease sector.
Expected follow-up The EMA will publish the outcomes of the COMP meeting in its official meeting report, typically within a few weeks. The next COMP meeting is scheduled for June 2026.
← Atlas › News › Health & Lifestyle